OCT starts a phase III study

This is a multicenter, double blind, randomized, placebo controlled phase III clinical trial to confirm the efficacy and safety of an investigational product to treat female patients with decrease or loss of sexual desire.

It is planned to screen more than 340 women aged 21-50. Randomized subjects will be allocated into two treatment arms. A total of 250 female patients will be enrolled in this study. The treatment duration will last up to 4 weeks and the follow-up period up to 8 weeks.

An interim analysis by an independent statistician will be done in this study. The total duration of the trial including enrollment period will be about 18 months. Up to 30 investigative sites in Russia will participate in the study.